glp-1 agonists vs bariatric surgery weight loss comparison GLP-1RAs offer comparable to with fewer side effects The role of glucagon-like peptide-1

Response rates vary by molecule newer agents such as tirzepatide and semaglutide yield higher responder rates (~86%91%) than older agents such as exenatide or liraglutide (~40%65%) (223) and vary by baseline BMI, sex, and glycemic status, with women and individuals with higher BMI responding better (222, 224)

Six models were fit with BrAC, perceived drunkenness, alcohol craving, appetite, blood glucose, and nausea scores as dependent variables, respectively (Supplemental Table 2)

Only a minority of studies, that is, four in Parkinsons disease 52,53,54,55 , five in substance-use disorders 111,113,115,116,117 , one in psychotic disorders 144 and two in mood disorders 178,179,182 , assessed the cognitive and mental health effects of GLP-1RAs in non-diabetic, non-obese populations

We systematically searched English and Chinese databases, including Embase, PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform, and Weipu website (VIP), based on the PICOS (Participants, Interventions, Comparisons, Outcomes, Study design) principles

Chronic elevation in insulin signaling molecules is a feature of insulin resistance [94], thus it is possible that results reflect insulin signaling dysfunction in participants treated with exenatide

Safety and Side Effects Like all GLP-1 medications, both liraglutide and semaglutide can cause some gastrointestinal distress including nausea, diarrhea, vomiting, reflux and constipation